The NeoAg Summit is the leading industry-focused meeting dedicated to ensuring improved identification, accelerated clinical translation and effectively scaled out manufacturing to ensure the successful clinical and commercial development of truly individualized neoantigen-based vaccines and cellular immunotherapies.

In a rapidly evolving field, cancer vaccines and immunotherapies have seen mixed results due to challenges targeting the tumor, especially in solid tumor indications. As such, the potential to specifically target true cancer antigens and shared neoantigens provides huge potential to successfully target tumors and cure cancer.

Seize your opportunity at the NeoAg Summit to benchmark your therapy, exclusively network with 250+ key thought leaders and overcome major challenges from prediction and discovery to clinical development, manufacturing and commercialization.